Search company, investor...
Syndesi Therapeutics company logo

Syndesi Therapeutics

Founded Year



Acquired | Acquired

Total Raised




About Syndesi Therapeutics

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer's Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB.On March 1st, 2022, Syndesi Therapeutics was acquired by AbbVie at a valuation between $130M and $1B.

Headquarters Location

Chemin du Cyclotron 6

Louvain-la-Neuve, 1348,


Missing: Syndesi Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Syndesi Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Syndesi Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Syndesi Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Syndesi Therapeutics News

Kynos Therapeutics announces the expansion of its leadership team with the appointment of Jonathan Savidge as CEO

Nov 11, 2022

Edinburgh UK, 11th November 2022 – Kynos Therapeutics Ltd, an immune-metabolic company with world-leading expertise in the kynurenine pathway and kynurenine 3-monooxygenase (KMO) biology, today announced the appointment Dr Jonathan Savidge as CEO. The appointment is part of the next stage in the development of the company as it moves novel KMO inhibitors into clinical development. Jonathan brings a wealth of experience in fundraising and business and corporate development, having previously been founding CEO of Syndesi Therapeutics and concluding an acquisition deal earlier this year with a headline value of $1BN. Jonathan joins the Kynos Therapeutics leadership team comprising the founders, Professors Damian Mole and Scott Webster and CFO Alison Strutt. Professor Mole, founding CEO, will continue to play a key role in the company as scientific expert and champion, assuming the title of Chief Scientific Officer. Professor Webster will continue to oversee the development of molecules into the clinic as Chief Technology Officer. Commenting on his appointment as CEO, Jonathan Savidge said “I am thrilled to join the team at Kynos at this exciting time as the company prepares to move into clinical development. The Kynos founders have built a world-leading expertise in the KMO target with a lead molecule poised to enter the clinic. I look forward to working with them, the rest of the Kynos team and the Board to progress development of these innovative KMO inhibitors and evolve the company to its next stage.” Kynos Therapeutics founder and CSO Damian Mole said “I am delighted to welcome Jonathan to the company. His track record and complementary skill set significantly strengthens the existing Kynos leadership team and will accelerate the development of the company and its KMO platform.” About Kynos Therapeutics Kynos Therapeutics is developing an innovative pipeline of first-in-class kynurenine 3-monooxygenase (KMO) inhibitors. KMO plays a major role in the regulation of inflammation, acting at the interface between inflammation, immunity and metabolism, and inhibition of KMO has therapeutic potential in a range of indications. Spun out from the University of Edinburgh, Kynos leverages a decade of drug discovery research on KMO inhibitors originally co-developed through a collaboration between GSK and the University of Edinburgh and now exclusively licensed to Kynos. Based in Edinburgh, UK, the company is backed by founding investor Epidarex Capital as well as IP Group plc and Scottish Enterprise with additional non-dilutive funding from Innovate UK. For more information, please visit: . Please click here to view the original press release. Search

Syndesi Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Syndesi Therapeutics Rank

Syndesi Therapeutics Frequently Asked Questions (FAQ)

  • When was Syndesi Therapeutics founded?

    Syndesi Therapeutics was founded in 2017.

  • Where is Syndesi Therapeutics's headquarters?

    Syndesi Therapeutics's headquarters is located at Chemin du Cyclotron 6, Louvain-la-Neuve.

  • What is Syndesi Therapeutics's latest funding round?

    Syndesi Therapeutics's latest funding round is Acquired.

  • How much did Syndesi Therapeutics raise?

    Syndesi Therapeutics raised a total of $24.4M.

  • Who are the investors of Syndesi Therapeutics?

    Investors of Syndesi Therapeutics include AbbVie, Societe Regionale d'Investissement de Wallonie, Johnson & Johnson Innovation, V-Bio Ventures, Novo Seeds and 8 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.